

AI-Integrated Green Chemistry in Pharmaceutical Synthesis: Toward Sustainable and Intelligent Drug Discovery

Vithal R. Bhandare¹, Hardik K. Naik², Karen R. Fernandes³, Ambreen Kauser Laeeque Ahmed⁴, Muskan Khanam⁵, Faizan Ahmed Md Israeel⁶

¹Asst. Professor, Department of Pharmaceutical Chemistry, Goa College of Pharmacy, Panaji, Goa

²Asst. Professor, Department of Pharmaceutical Chemistry, Srinivas College of Pharmacy, Valachil, Mangalore

³Research Scholar, Department of Pharmaceutical Chemistry, Goa College of Pharmacy, Panaji, Goa

⁴Asst. Professor, Department of Pharmaceutical Chemistry, Royal College of Pharmaceutical Education and Research Sayne Khurd Malegaon

⁵Lecturer, Department of Pharmaceutical Quality Assurance, Raje Laxman Singh Bhonsle College of Pharmacy Akola

⁶Asst. Professor, Department of Pharmaceutical Chemistry, Royal College of Pharmaceutical Education and Research, Sayne Khurd, Malegaon

Graphical Abstract




Figure 1. Graphical Abstract

Abstract—Pharmaceutical synthesis is undergoing a major transformation through the convergence of artificial intelligence (AI), machine learning, automation and green chemistry. Conventional drug discovery and process development often involve iterative

experimentation, multistep synthesis, extensive solvent use, energy consumption and chemical waste. Green chemistry provides principles for minimizing these impacts, while AI enables molecular design, retrosynthetic planning, reaction prediction, condition optimization and automated experimentation. AI-assisted route selection can evaluate synthetic feasibility alongside sustainability metrics such as atom economy, process mass intensity and E-factor. Generative models can support molecular design by considering pharmacological properties, synthetic accessibility and environmental constraints. Bayesian optimization, robotics and process analytical technology can further enable closed-loop synthesis. Integration with biocatalysis, flow chemistry, mechanochemistry, electrochemistry and digital technologies may improve resource efficiency. However, computational energy demand, data quality, model interpretability and regulatory validation remain challenges. This review examines AI-integrated green chemistry as a framework for sustainable, efficient and intelligent pharmaceutical synthesis.

Index Terms—Artificial intelligence; Green chemistry; Pharmaceutical synthesis; Sustainable drug discovery; Machine learning; Retrosynthesis; Green metrics; Autonomous laboratories

I. INTRODUCTION

Pharmaceutical synthesis is a multidisciplinary activity involving medicinal chemistry, organic synthesis, process chemistry, analytical science and manufacturing. The development of a new drug candidate can require repeated cycles of molecular modification and experimental synthesis. Although these cycles are essential for optimizing biological properties, they can also consume substantial quantities of starting materials, solvents and energy. Green chemistry seeks to reduce these burdens by preventing waste and improving the efficiency and safety of chemical transformations. [1]

The sustainability of pharmaceutical synthesis is multidimensional. A process may provide a high isolated yield but still generate considerable waste because of excess reagents, protecting groups, solvent-intensive purification or inefficient work-up. Consequently, environmental performance cannot be represented by yield alone. Process mass intensity, E-factor, atom economy, solvent selection, energy demand and hazard are complementary considerations that can provide a broader assessment of synthetic sustainability. [2]

Quantitative green metrics provide an important bridge between qualitative green-chemistry principles and process decision-making. Atom economy evaluates the proportion of reactant atoms incorporated into the desired product, whereas E-factor and process mass intensity consider material consumption and waste generation. These metrics can be used to compare alternative synthetic strategies and identify opportunities for process improvement. [3]

Artificial intelligence has developed rapidly in chemistry because of advances in machine learning, molecular representations and large reaction datasets. Transformer-based systems have demonstrated strong performance in reaction prediction and can estimate likely products from reaction inputs. [4]

Retrosynthetic planning has also benefited from the integration of deep neural networks and symbolic search. Modern systems can explore large reaction spaces and propose multistep synthetic routes, helping chemists identify plausible pathways for complex molecules. [5]

Recent developments are moving beyond chemical feasibility toward integrated sustainability. AI-driven synthesis platforms increasingly combine

retrosynthesis, reaction optimization, robotics and green metrics, creating the possibility of selecting routes according to multiple objectives rather than yield or step count alone. [6]

Process mass intensity is particularly relevant to pharmaceutical synthesis because it accounts for the total mass of materials used relative to the mass of product obtained. Its use provides a practical way to identify material inefficiencies that may not be apparent from reaction yield. [7]

Atom economy provides another important design-level metric. The concept encourages synthetic transformations in which a greater fraction of the atoms presents in the starting materials become part of the desired product, thereby reducing by-product formation. [8]

Solvent selection is equally important because solvents can dominate material usage and contribute to occupational, environmental and energy burdens. Structured solvent-selection guides such as CHEM21 provide systematic approaches for considering solvent safety and environmental characteristics. [9]

1.1. Introduction to Green Chemistry in Pharmaceutical Synthesis

Green chemistry emphasizes prevention of waste, improved atom economy, safer chemical synthesis, safer solvents, catalysis, energy efficiency, renewable feedstocks, reduced derivatization and inherently safer processes. In pharmaceutical chemistry, these principles must be adapted to the complexity of drug discovery and manufacturing, where high selectivity, purity and regulatory requirements are essential. [10]

1.2. Role of Green Metrics

Green metrics convert sustainability concepts into measurable parameters. Atom economy is useful at the reaction design stage, while PMI and E-factor provide broader process-level information. Additional indicators can consider solvent hazard, energy use, toxicity, catalyst scarcity and life-cycle effects. [11]

II. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL CHEMISTRY

AI encompasses machine learning, deep learning, graph neural networks, transformers, reinforcement learning and generative models. In pharmaceutical chemistry, these methods can be applied to molecular-

property prediction, virtual screening, reaction prediction, retrosynthesis and process optimization.[12]

III. AI-ASSISTED RETROSYNTHETIC PLANNING

Retrosynthesis converts a target molecule into simpler precursors through a sequence of chemically plausible transformations. AI systems can combine learned reaction models with symbolic search to generate and rank possible routes. This capability is particularly valuable for complex pharmaceutical targets.[13]

3.1. Sustainability-Aware Route Selection

Route selection should consider more than synthetic feasibility.

A sustainable route may involve fewer steps, higher selectivity, lower solvent consumption, safer reagents and reduced energy demand. AI can provide the computational infrastructure needed to compare many alternative routes.[14]

3.2. AI and Green Chemistry Integration

AI is not automatically green. A model can identify an efficient reaction that relies on hazardous reagents or energy-intensive conditions. Therefore, green criteria should be explicitly included in computational objectives.[15]

3.3. AI-Based Reaction Prediction

Reaction prediction models learn relationships between chemical inputs and products. Transformer-based architectures have demonstrated strong performance and can provide uncertainty estimates, creating opportunities for prioritizing experiments with high predicted value. Reaction prediction can reduce unsuccessful experiments and improve route planning.[16]

IV. AI-BASED REACTION-CONDITION OPTIMIZATION

Reaction optimization often requires exploration of temperature, solvent, catalyst, concentration, reaction time and reagent ratios. AI can model these relationships and prioritize experiments. Bayesian optimization is especially useful when experimental trials are expensive.[17]

V. AI-ASSISTED MOLECULAR DESIGN FOR SUSTAINABLE DRUG DISCOVERY

The conventional drug-discovery process frequently generates a large number of molecular candidates that subsequently fail because of inadequate potency, selectivity, pharmacokinetics, toxicity or synthetic limitations. Every experimentally synthesized compound consumes chemical resources and generates associated waste. Consequently, improving molecular prioritization before laboratory synthesis represents an important sustainability opportunity.

AI-based molecular-property prediction can reduce this burden by estimating biological and physicochemical properties before compounds are synthesized. Machine-learning models can analyze molecular descriptors, fingerprints, graph representations and learned molecular embeddings to predict parameters associated with potency, solubility, permeability, metabolic stability and toxicity. By prioritizing molecules with a higher probability of satisfying predefined criteria, computational screening can potentially reduce unnecessary experimental synthesis.

The sustainability implications become more significant when synthetic accessibility is incorporated into molecular selection. A molecule with excellent predicted biological activity may require a highly complex synthesis, whereas another candidate with comparable predicted activity may be accessible through a shorter and less resource-intensive pathway. Therefore, future AI-based drug design systems should evaluate both biological desirability and synthetic sustainability during molecular prioritization.

Generative AI further expands this possibility by creating new molecular structures rather than merely ranking existing compounds. Generative models can be constrained by molecular properties, structural motifs and synthetic feasibility, allowing candidate generation to become more closely connected with practical pharmaceutical synthesis. [18]

VI. GENERATIVE AI AND SUSTAINABLE MOLECULAR DESIGN

Generative artificial intelligence has become an important area of computational medicinal chemistry. Variational autoencoders, generative adversarial

networks, reinforcement-learning systems and transformer-based architectures can generate molecular structures according to predefined objectives.

In pharmaceutical discovery, molecular generation can be directed toward potency, selectivity, physicochemical properties and drug-likeness. However, the same computational framework can be expanded to include environmental and synthetic objectives.

A generative model could assign a composite objective to each candidate: biological activity +

selectivity + ADMET profile + synthetic accessibility + sustainability. This approach could discourage the generation of structures that are biologically attractive but difficult to manufacture.

The integration of synthetic accessibility into generative molecular design has become increasingly important because molecular novelty without practical synthesis provides limited value for experimental drug discovery. AI-based synthesis planning can therefore function as a feedback mechanism for molecular generation, allowing the model to preferentially create structures with plausible synthetic pathways. [19]




Figure 2. Proposed Sustainable Generative-Design Cycle

6.1. AI-Based Multi-Objective Retrosynthesis

Retrosynthesis is traditionally evaluated according to whether a target molecule can be converted into commercially or synthetically accessible precursors. However, a sustainable retrosynthetic platform must consider a broader set of objectives.

A route may be synthetically valid but undesirable because it contains numerous steps, low-yielding reactions, stoichiometric reagents, hazardous solvents or energy-intensive transformations. Consequently, sustainability should be incorporated during route ranking rather than evaluated after the synthetic route has already been selected.

One potential framework is: Green Route Score = f (step count, yield, atom economy, PMI, E-factor, solvent burden, hazard, energy and cost).

The exact weighting should depend on the intended process and should not be treated as a universal formula. Different pharmaceutical processes may assign different importance to waste, energy, solvent recovery, safety or raw-material availability.

AI can provide the computational infrastructure required to compare thousands of candidate pathways. Instead of manually evaluating a limited number of synthetic routes, algorithms can generate a large route space and filter candidates using predefined constraints.

Recent developments in algorithm-assisted synthesis have increasingly emphasized the need to combine synthetic feasibility with sustainability-related criteria rather than treating green chemistry as a separate downstream assessment. [20]

6.2. AI-Assisted Solvent Selection

Solvents can constitute a substantial fraction of the material input associated with pharmaceutical synthesis. Their selection influence's reaction performance, safety, toxicity, environmental impact, separation, recovery and energy requirements.

Traditional solvent selection commonly relies on solvent guides developed from experimental knowledge and health, safety and environmental

assessments. These resources remain valuable, but they do not necessarily account for the specific requirements of every reaction.

Machine-learning systems could complement conventional solvent selection by learning relationships between molecular properties, reaction conditions and reaction outcomes. A model could potentially predict whether a transformation is compatible with a particular solvent while a separate sustainability layer evaluates solvent-related environmental characteristics.

The CHEM21 methodology demonstrated the value of systematic solvent selection based on safety, health and environmental criteria. [21]

The future integration of AI with such frameworks could enable reaction-specific solvent optimization. Instead of asking only whether a solvent supports a reaction, the computational system could ask whether the solvent supports the desired transformation, is compatible with the reagents and catalyst, can be recovered, has reasonable energy requirements for removal, avoids downstream purification burdens and has a safer alternative.

6.3. AI-Assisted Catalyst and Reagent Selection

Catalysis is one of the central principles of green chemistry because catalysts can increase reaction rates and selectivity while reducing stoichiometric waste.

Pharmaceutical synthesis frequently uses transition-metal catalysts, organocatalysts, photocatalysts, enzymes and heterogeneous catalysts. Choosing an appropriate catalyst may require extensive screening because catalyst identity, ligand structure, loading, solvent and reaction conditions can interact strongly. Machine learning can analyze previous experimental data to identify relationships between catalyst characteristics and reaction outcomes. Such models can prioritize candidate catalysts before experimental screening.

For example, a reaction-optimization model could consider catalyst identity, ligand, solvent, temperature, concentration and reagent ratio simultaneously. Bayesian optimization could then select the next experiment according to the predicted probability of achieving a desirable outcome.[22]

6.4. AI and Biocatalysis

Biocatalysis represents an important component of sustainable pharmaceutical synthesis because

enzymes can provide high chemo-, regio- and stereoselectivity under comparatively mild conditions. Enzymatic synthesis can reduce the need for protecting groups, harsh reagents and extreme reaction conditions in suitable transformations. However, enzyme selection and engineering can be challenging because activity and selectivity depend on substrate structure, enzyme sequence, reaction medium and operating conditions.[23]

AI can contribute by predicting enzyme–substrate compatibility, identifying promising enzyme variants and guiding protein engineering.

Table 1. Potential AI Contributions to Sustainable Biocatalysis

AI application	Target	Sustainability opportunity
Enzyme activity prediction	Catalytic performance	Reduces screening
Sequence–function modeling	Enzyme engineering	Limits mutation libraries
Substrate prediction	Enzyme–substrate compatibility	Reduces failed experiments
Reaction optimization	pH, temperature, loading	Improves resource efficiency
Stability prediction	Operational stability	Supports longer catalyst use
Protein generation	Novel enzyme variants	Expands biocatalytic options

6.4. AI-Driven Retro-Biosynthesis

Retro-biosynthesis applies retrosynthetic reasoning to enzymatic and biological transformations. Instead of considering only conventional synthetic reactions, computational systems identify enzymatic steps capable of transforming a target structure into simpler precursors.

The approach can expand the reaction space available to synthetic planning. For certain pharmaceutical intermediates, an enzymatic transformation may replace a conventional chemical reaction involving hazardous reagents or energy-intensive conditions.

AI can support retro-biosynthesis by predicting enzyme compatibility and integrating biological transformations into synthetic route planning.

This is particularly relevant to hybrid synthesis, where chemical and enzymatic reactions are combined within the same manufacturing route.[24]

6.5. Flow Chemistry and AI

Continuous-flow chemistry offers several advantages for pharmaceutical synthesis, including improved heat and mass transfer, enhanced process control, reduced reaction volume and opportunities for intensified manufacturing.

Flow systems can also facilitate hazardous reactions by maintaining small reaction inventories and precisely controlling reaction conditions.

However, flow processes involve several interconnected variables, including flow rate, residence time, temperature, pressure, concentration and reactor configuration. Optimization can therefore become computationally complex [25].

AI and machine learning can provide a mechanism for optimizing these parameters using experimental feedback.




Figure 3. Legend: The figure should depict an automated continuous-flow synthesis platform in which an AI system proposes operating conditions, a flow reactor performs the transformation and inline analytical instruments measure the reaction outcome. Experimental data are returned to the computational model, which updates the next set of operating parameters.

VII. MECHANOCHEMISTRY AS AN AI-COMPATIBLE GREEN TECHNOLOGY

Mechanochemistry involves inducing chemical transformations through mechanical energy, often using ball milling or related techniques. In appropriate reactions, mechanochemical approaches can substantially reduce or eliminate conventional solvent use.

The sustainability potential of mechanochemistry has attracted significant interest because solvent reduction can directly influence PMI and waste generation. However, mechanochemical reactions can involve multiple interacting parameters, including milling

frequency, milling time, vessel characteristics, ball size, ball-to-powder ratio, additives and temperature. AI-based optimization could potentially identify useful parameter combinations without exhaustive experimental screening.[26]

VIII. ELECTROCHEMICAL AND PHOTOCHEMICAL SYNTHESIS

Electrochemical synthesis can replace chemical oxidants or reductants with electrons as reagents, while photochemical synthesis can use light energy to enable transformations that may be difficult under conventional thermal conditions.

These approaches can contribute to sustainable synthesis when appropriate reaction conditions and energy sources are available.

AI-based optimization can provide a systematic approach to exploring variables such as electrode composition, current density, potential, wavelength, light intensity, solvent, concentration and reaction time.[27]

IX. BAYESIAN OPTIMIZATION AND AUTONOMOUS EXPERIMENTATION

Bayesian optimization has become particularly relevant to chemical experimentation because laboratory experiments can be expensive in terms of time, materials and human effort.

Initial experimental data generation.

Construction of a surrogate predictive model.

Quantification of uncertainty.

Selection of the next experiment.

Experimental execution.

Addition of the new result to the dataset.

Recalculation of the model.

Repetition until an appropriate objective is achieved.

The approach is highly compatible with green chemistry because reducing the number of experiments can reduce chemical consumption and waste.[28]

9.1. Self-Driving Laboratories in Pharmaceutical Synthesis

A self-driving laboratory integrates computational decision-making, robotic experimentation and analytical measurement into a closed-loop system.

The basic architecture is: AI prediction → robotic experiment → analytical measurement → data processing → AI prediction.

This differs from conventional automation because the system is not simply executing a predefined experimental sequence. Instead, experimental results influence the next experiment selected by the algorithm.

Recent developments in autonomous chemical research have demonstrated the potential of combining

machine learning, robotics and automated analysis to accelerate experimental optimization. [29]

Table 2. Components of an AI-Driven Self-Driving Laboratory

Component	Function	Green-chemistry relevance
AI model	Predicts experimental outcome	Reduces inefficient experiments
Optimization algorithm	Selects next experiment	Minimizes experimental count
Robotic platform	Performs experiments	Improves reproducibility
Analytical system	Measure's reaction output	Enables rapid feedback
Data infrastructure	Stores experimental results	Supports continuous learning
Sustainability module	Evaluates green metrics	Prevents yield-only optimization

9.2. AI-Integrated Green Metrics

One of the most important developments required for sustainable AI-driven synthesis is the incorporation of green metrics directly into computational algorithms.

A conventional AI synthesis system may optimize: Yield → Selectivity → Route length.

A sustainability-aware system could optimize: Yield → Selectivity → Route length → PMI → E-factor → Atom economy → Solvent burden → Hazard → Energy.[30]

9.3. Integrating Green Metrics into AI Objective Functions

A central challenge is determining how different sustainability indicators should be combined. A route may have excellent atom economy but poor solvent performance. Another may have low PMI but require a catalyst containing a scarce metal. Therefore, no single green metric can adequately represent the environmental performance of every pharmaceutical synthesis.




Figure 4. Legend: The architecture illustrates how chemical and sustainability objectives can be incorporated into a single computational–experimental loop. Rather than optimizing isolated reaction yield, the platform simultaneously evaluates pharmaceutical performance, synthetic feasibility and environmental characteristics.

AI provides an opportunity to develop multi-objective optimization rather than relying on one universal sustainability score.

maximizing isolated yield;
maximizing selectivity;
minimizing reaction steps;
maximizing atom economy;
minimizing PMI;
minimizing E-factor;
minimizing solvent hazard;
minimizing energy requirements;
minimizing hazardous reagent use;
maximizing catalyst efficiency.

Instead of producing one numerical green score, future platforms could provide a Pareto frontier of chemically feasible routes. This would allow process chemists to compare trade-offs between different routes rather than concealing those trade-offs within a single arbitrary score.[31]

9.4. AI and Circular Pharmaceutical Chemistry

Circular chemistry aims to minimize resource depletion and maintain materials within productive cycles. In pharmaceutical synthesis, circular principles can be applied to solvent recovery, catalyst recycling, waste valorization, renewable feedstocks and recovery of valuable intermediates. AI could help identify

opportunities for solvent recycling, catalyst recovery, by-product valorization and renewable feedstock substitution. [32]

X. AI-ENABLED PROCESS ANALYTICAL TECHNOLOGY

Process Analytical Technology involves monitoring and controlling pharmaceutical processes using timely measurements of critical process parameters and quality attributes. AI can enhance PAT by identifying patterns within complex analytical datasets obtained from spectroscopy, chromatography, imaging and sensors.

real-time reaction monitoring;
prediction of reaction completion;
impurity detection;
endpoint prediction;
crystallization monitoring;
particle-size prediction;
process deviation detection.

XI. DATA INFRASTRUCTURE FOR AI-INTEGRATED GREEN CHEMISTRY

The effectiveness of AI depends strongly on the quality of the data used for model development.

Chemical datasets can contain missing reaction conditions, inconsistent nomenclature, incomplete yields, duplicate records, publication bias and variations in experimental reporting.

Green metrics introduce additional data requirements. Calculating PMI accurately requires information about solvents, reagents, quantities and work-up operations, which are not consistently reported in many reaction databases.[33]

Table 3. Proposed Sustainable Reaction Dataset

Data category	Examples
Chemical identity	Reactants, products, intermediates
Reaction conditions	Temperature, pressure, time
Reagents	Identity and stoichiometry
Solvents	Identity, volume, recovery
Catalyst	Identity and loading
Performance	Yield, selectivity
Waste	By-products, work-up materials
Energy	Heating, cooling, irradiation
Green metrics	PMI, E-factor, atom economy
Safety	Hazard classifications
Scale	Laboratory or manufacturing scale

XII. OVERALL CONCEPTUAL FRAMEWORK

The integration of AI and green chemistry can be viewed as a five-layer system: molecular intelligence, synthetic intelligence, sustainability intelligence, experimental intelligence and learning intelligence [34].

Table 4. Five-Layer Framework for AI-Integrated Green Pharmaceutical Synthesis

Layer	Principal technology	Primary function	Expected sustainability benefit
Molecular intelligence	Generative AI	Candidate design	Fewer unnecessary syntheses
Synthetic intelligence	Retrosynthesis	Route generation	Alternative route discovery
Sustainability intelligence	Green metrics	Route evaluation	Waste/resource reduction
Experimental intelligence	Robotics	Automated synthesis	Reproducibility and efficiency
Learning intelligence	Machine learning	Closed-loop improvement	Reduced experimental burden

12.1. Recent Advances in AI-Integrated Green Pharmaceutical Synthesis

The integration of artificial intelligence with green chemistry has progressed from isolated prediction models toward interconnected systems that combine molecular design, reaction planning, optimization, automation and sustainability assessment. Recent literature increasingly describes AI not simply as a predictive technology but as part of a broader digital infrastructure for sustainable chemical development. [27]

One important development is the transition from single-task machine-learning models to integrated platforms. Earlier applications often focused on one problem, such as reaction-yield prediction or retrosynthetic analysis. More recent systems increasingly combine synthesis planning with experimental optimization, robotic execution and analytical feedback. This development is particularly relevant to pharmaceutical chemistry because the largest efficiency gains may arise when several computational and experimental stages are connected rather than optimized independently. [35]

Recent AI-driven synthesis systems increasingly emphasize sustainability metrics alongside retrosynthesis, reaction optimization, robotic automation and large language models.

12.2. AI-Assisted Solvent and Process-Space Prediction

Machine-learning approaches have demonstrated that chemical structure and molecular descriptors can be used to predict properties relevant to solvent selection and solubility. Such models illustrate how computational methods can reduce empirical trial-and-error in solvent-dependent processes.

For pharmaceutical synthesis, solvent prediction could be extended beyond solubility to include reaction conversion, selectivity, crystallization behavior and downstream separation.

An integrated model could therefore evaluate reaction compatibility, solubility, safety, environmental profile and separation performance rather than selecting solvents solely according to reaction yield.[36]

12.3. AI and Enzyme Engineering for Pharmaceutical Synthesis

Enzyme engineering is increasingly important for the synthesis of pharmaceutical intermediates and active

pharmaceutical ingredients. Directed evolution, computational design and high-throughput screening have expanded the practical range of biocatalytic transformations. AI can complement these approaches by predicting the effect of sequence modifications on enzyme activity, stability and selectivity. Instead of experimentally testing every possible mutation, machine-learning models can prioritize smaller libraries enriched for potentially useful variants. Recent multidisciplinary work has highlighted the interaction between protein engineering, computational biology and pharmaceutical biocatalysis. [37]

12.4. AI-Integrated Flow Chemistry

Flow chemistry provides an important experimental platform for AI because many process parameters can be controlled electronically and measured continuously.

Variables such as flow rate, residence time, temperature, pressure, reagent concentration, mixing ratio, catalyst loading and reactor configuration can be changed systematically.

Computer-aided automated flow synthesis is increasingly being explored as a route toward more efficient and scalable chemical experimentation, with AI-assisted design, automated process control and autonomous optimization emerging as important components. [38]

12.5. AI-Assisted Electrochemical Synthesis

Electrosynthesis offers opportunities to replace conventional oxidizing or reducing reagents with electrical energy. Nevertheless, electrochemical optimization can involve a high-dimensional parameter space because electrode composition, electrolyte, solvent, potential, current density and cell architecture can influence reaction performance.

Machine-learning approaches are being applied to these complex optimization problems. Recent work has demonstrated data-driven optimization of electrochemical reactions involving multiple experimental variables. [38]

12.6. AI-Enabled Autonomous Chemical Experimentation

Autonomous experimentation represents one of the most significant technological developments in modern synthetic chemistry.

A self-driving platform can combine reaction planning, automated reagent handling, robotic experimentation, analytical measurement, machine-learning prediction and iterative optimization.

The 2020 demonstration of a mobile robotic chemist illustrated the feasibility of integrating robotic laboratory operation with algorithmic decision-making for experimental search.

More recent reviews indicate that autonomous synthesis is developing toward closed-loop systems in which machine learning controls experimental selection while automation performs physical operations. However, purification and analytical interpretation remain important limitations. [38]

XIII. DIGITAL TWINS AND PHARMACEUTICAL PROCESS DEVELOPMENT

Digital twins provide a computational representation of a physical process that can be updated using experimental or manufacturing data.

Within pharmaceutical manufacturing, a digital twin could represent a reaction, crystallization process, continuous-flow operation or complete manufacturing unit.

AI models could use the digital representation to predict how changes in operating parameters influence quality and sustainability. Recent pharmaceutical research has proposed integrating AI, machine learning, digital twins and advanced process analytics into quality-by-digital-design frameworks. [39]

XIV. PROCESS ANALYTICAL TECHNOLOGY AND REAL-TIME OPTIMIZATION

Process Analytical Technology provides the measurement infrastructure required for closed-loop AI.

Potential analytical inputs include near-infrared spectroscopy, Raman spectroscopy, infrared spectroscopy, high-performance liquid chromatography, mass spectrometry, particle-size analysis, temperature sensors, pressure sensors and online concentration measurements.

AI can transform these measurements into process decisions, moving pharmaceutical manufacturing toward adaptive process control.[39]

14.1. Quality by Digital Design and Sustainable Manufacturing

Quality by Design establishes relationships between material attributes, process parameters and critical quality attributes.

AI can extend this concept by enabling continuous learning from process data.

Quality by Digital Design can incorporate predictive analytics, digital twins, process monitoring and machine learning to support adaptive manufacturing. Recent pharmaceutical manufacturing research identifies AI-integrated digital design as a mechanism for real-time optimization, predictive control, energy reduction and improved process monitoring. [34]

14.2. Pharmaceutical Applications

AI-integrated green chemistry can potentially influence multiple stages of pharmaceutical development.

During early discovery, AI can prioritize compounds according to biological activity, physicochemical properties and predicted synthetic feasibility.

During hit-to-lead and lead optimization, AI can identify analogues satisfying multiple criteria simultaneously, reducing inefficient compound generation.

During process development, AI can assist with reaction conditions, solvent selection, catalyst selection and process parameters.

During scale-up and continuous manufacturing, AI and digital models may help identify process deviations and optimize operating conditions.[40]

XV. INDUSTRIAL AND TRANSLATIONAL RELEVANCE

The industrial relevance of AI-integrated green chemistry lies in its ability to connect discovery chemistry with process chemistry.

Historically, medicinal chemistry and manufacturing-process development have often been treated as sequential activities.

A sustainability-aware digital platform can begin incorporating manufacturing considerations during molecular design.

Digitalization is increasingly being discussed as a means of improving sustainability throughout the pharmaceutical value chain. [36,40]

15.1. Clinical Studies and Human Evidence

Direct clinical studies evaluating AI-integrated green chemistry as a therapeutic intervention are not the primary evidence base for this field.

The principal evidence currently comes from computational studies, synthetic chemistry experiments, reaction-optimization studies, autonomous laboratory demonstrations, biocatalytic process development and pharmaceutical manufacturing research.

Relevant translational metrics therefore include time-to-synthesis, number of experiments, isolated yield, process mass intensity, E-factor, energy consumption, solvent burden, reproducibility and scalability.[37]

XVI. CHALLENGES AND LIMITATIONS

Despite rapid development, AI-integrated green chemistry faces substantial scientific and technological limitations.

Data quality:

AI models depend on experimental data. Chemical datasets may contain incomplete conditions, inconsistent nomenclature, missing yields and publication bias.

Dataset bias:

Models trained predominantly on published successful reactions may underestimate failed reactions and unusual chemical behavior.

Interpretability:

Some deep-learning models provide accurate predictions but limited mechanistic explanation.

Reproducibility:

Reaction outcomes can vary because of equipment, mixing, reagent quality, scale and analytical procedures.

Hardware interoperability:

Autonomous laboratories require communication between robotic systems, analytical instruments, reaction platforms and data infrastructure.

Economic barriers:

Robotic laboratories and advanced analytical systems require substantial capital investment.

Energy consumption of AI: Large computational models may require substantial electricity for training and deployment.

Regulatory considerations:

Pharmaceutical manufacturing requires validated processes, traceability and documented decision-making.

Human oversight:

Chemical synthesis remains a domain where unexpected reactivity and context-dependent behavior are important.

Sustainability-metric limitations:

Green metrics provide valuable quantitative information but cannot fully represent every environmental consequence.[41]

XVII. FUTURE PERSPECTIVES

The next stage of development is likely to involve greater integration between AI, robotics, green chemistry, process analytics and digital manufacturing.

Sustainability-by-design systems should incorporate environmental considerations from the beginning

rather than treating sustainability as a post-processing filter.

AI systems should optimize multiple variables simultaneously, including potency, selectivity, ADMET, synthesis, cost, waste, energy and hazard.

The most practical future model may involve collaborative intelligence, in which AI performs high-dimensional search while chemists provide mechanistic interpretation and final experimental decisions.

Internationally standardized reaction datasets containing quantities, solvents, energy, waste and green metrics would substantially improve AI training. Future autonomous laboratories could evaluate not only reaction yield but also real-time sustainability indicators.

Digital twins could allow pharmaceutical processes to be optimized virtually before extensive physical experimentation.

AI could help identify routes that facilitate solvent recovery, catalyst recycling and valorization of side streams.

Explainability, traceability, validation and reproducibility will become increasingly important before AI systems can be widely deployed in regulated pharmaceutical manufacturing [41].




Figure 5. Sustainable Autonomous Pharmaceutical Laboratory

Therapeutic Target → Generative Molecular Design → AI Property Prediction → Synthetic Accessibility → AI Retrosynthesis → Green Route Evaluation → Solvent + Catalyst + Reagent Selection → Robotic Experiment → PAT / Analytical Measurement → AI Interpretation → Bayesian Optimization → Repeat Experiment → Scale-Up Simulation / Digital Twin → Sustainable Pharmaceutical Manufacturing.

The system should contain a continuous sustainability layer evaluating waste, solvent, energy, hazard, carbon and material efficiency.

XVIII. CRITICAL PERSPECTIVE

AI-integrated green chemistry should not be understood as the simple addition of artificial intelligence to conventional green chemistry. Its

significance lies in changing the decision structure of pharmaceutical synthesis.

Traditional development often follows Design → Synthesis → Optimization → Scale-Up → Sustainability Assessment. The emerging model is Design ↔ Synthesis ↔ Optimization ↔ Sustainability ↔ Experimental Feedback.

This circular architecture allows information from later stages to influence earlier decisions.

Technological sophistication alone does not guarantee sustainability. An AI model can recommend a highly efficient reaction that uses hazardous reagents, and a robotic laboratory can perform hundreds of experiments while consuming large quantities of solvent.

The appropriate objective is therefore AI-guided synthesis under explicit sustainability constraints. [42]

Table 4. AI–Green Chemistry Opportunities Across Drug Development

Stage	Conventional challenge	AI intervention	Potential sustainability effect
Molecular design	Large candidate space	Generative AI	Fewer unnecessary syntheses
Virtual screening	Expensive experiments	Predictive models	Reduced laboratory burden
Retrosynthesis	Limited route comparison	AI route generation	Alternative routes
Solvent selection	Trial-and-error	ML prediction	Reduced solvent experimentation
Reaction optimization	Large parameter space	Bayesian optimization	Fewer experiments
Process development	Manual optimization	Digital models	Improved efficiency
Manufacturing	Process variability	AI monitoring	Reduced deviations
Waste management	Complex streams	Data analytics	Better waste classification
Supply chain	Demand uncertainty	Predictive analytics	Resource optimization

XIX. CONCLUSION

The integration of artificial intelligence with green chemistry is emerging as a significant paradigm for the transformation of pharmaceutical synthesis. Conventional pharmaceutical development frequently relies on sequential cycles of molecular design, synthesis, purification, analysis and optimization. AI provides an opportunity to connect these stages through predictive modeling, retrosynthetic planning, generative molecular design, reaction optimization, automated experimentation and data-driven process control.

Green chemistry provides the sustainability framework within which these computational capabilities can be applied. Principles such as waste

prevention, atom economy, safer solvents and auxiliaries, catalysis, energy efficiency and renewable-resource utilization can be translated into measurable objectives for computational route selection. Importantly, AI should not be considered inherently sustainable. Its environmental value depends on whether computational and automated systems ultimately reduce material consumption, waste, hazardous inputs, energy demand and experimental burden. The next stage of synthesis planning is increasingly concerned with chemical correctness together with greenness, sustainability and circularity. [42]

AI-assisted retrosynthesis can expand the number of routes considered for a pharmaceutical target, while

machine-learning models can assist with reaction prediction, solvent selection, catalyst selection and reaction-condition optimization. Generative models can further connect molecular design with synthetic accessibility, creating opportunities for sustainability-by-design approaches.

The combination of Bayesian optimization, robotics and process analytical technology creates another important opportunity. Rather than performing large experimental matrices manually, autonomous platforms can select informative experiments, perform them robotically, measure their outcomes and use the resulting data to guide subsequent experiments. Demonstrations of autonomous robotic experimentation have shown that algorithm-driven experimental search can explore multidimensional chemical spaces efficiently. [43]

Green metrics are essential for ensuring that AI optimization does not focus exclusively on reaction yield. Process mass intensity, E-factor, atom economy, solvent burden, energy consumption and hazard-related indicators can provide complementary information about the sustainability of alternative routes. PMI has become an important pharmaceutical-industry metric because it considers the total material input associated with a process rather than focusing solely on isolated waste streams.

The future therefore lies in multi-objective AI-assisted synthesis, in which pharmaceutical performance, synthetic feasibility, economic considerations and sustainability are evaluated together. A computationally generated route should ideally be assessed not only for whether it can produce the desired molecule but also for how much material, energy, solvent and hazardous chemistry are required.[44]

The convergence of AI with flow chemistry, biocatalysis, electrochemistry, mechanochemistry, continuous manufacturing, digital twins and autonomous laboratories could create increasingly integrated pharmaceutical-production systems. Continuous manufacturing has demonstrated potential to reduce process footprints and improve resource efficiency when appropriately implemented.

Ultimately, AI-integrated green chemistry should be regarded as an enabling framework rather than a single technology. Its success will depend on high-quality chemical and sustainability datasets, transparent algorithms, standardized green metrics, interoperable

laboratory hardware, regulatory acceptance and appropriate human oversight.[45]

XX. FUTURE PERSPECTIVES

Sustainability-by-design: introduce environmental considerations during molecular generation.

Multi-objective route optimization: compare feasible routes using yield, step count, PMI, E-factor, energy, cost and hazard.

Green reaction databases: standardize experimental quantities, solvents, catalysts, work-up, energy and sustainability data.

AI-assisted biocatalytic synthesis: integrate enzyme engineering with retrosynthetic planning.

Autonomous sustainable laboratories: optimize product quality while minimizing material use, waste, hazard and energy.

Digital twins: evaluate alternative reaction and process conditions before extensive physical experimentation.

AI and circularity: identify solvent recovery, catalyst recycling and waste-valorization opportunities.

Regulatory and explainable AI: improve transparency, traceability, validation and reproducibility.

Life-cycle assessment integration: connect reaction-level metrics with upstream and downstream environmental impacts.

Human–Ai Collaborative Chemistry: Combine Computational Search with Expert Mechanistic Interpretation and Scientific Judgment.

REFERENCES

- [1] B. A. Grzybowski, A. Żądło-Dobrowolska, N. Onishchenko, and E. S. Larsen, “Sustainable production of chemicals by algorithm-assisted (bio)synthesis,” *Nat. Rev. Bioeng.*, vol. 3, pp. 791–803, 2025, doi: 10.1038/s44222-025-00312-7.
- [2] P. T. Anastas and J. C. Warner, *Green Chemistry: Theory and Practice*. New York, NY, USA: Oxford University Press, 1998.
- [3] C. Jiménez-González, A. D. Curzons, D. J. C. Constable, and V. L. Cunningham, “Cradle-to-gate life cycle assessment of pharmaceutical processes,” *Int. J. Life Cycle Assess.*, vol. 9, pp. 114–121, 2004.
- [4] R. A. Sheldon, “The E factor: Fifteen years on,” *Green Chem.*, vol. 9, pp. 1273–1283, 2007.

- [5] P. Schwaller, T. Laino, T. Gaudin, P. Bolgar, C. A. Hunter, C. Bekas, *et al.*, “Molecular Transformer: A model for uncertainty-calibrated chemical reaction prediction,” *ACS Cent. Sci.*, vol. 5, no. 9, pp. 1572–1583, 2019.
- [6] M. H. S. Segler, M. Preuss, and M. P. Waller, “Planning chemical syntheses with deep neural networks and symbolic AI,” *Nature*, vol. 555, pp. 604–610, 2018.
- [7] A. Gangwal and A. Lavecchia, “AI-driven synthesis in medicinal chemistry: Integrating large language models, robotic automation, and sustainability metrics to accelerate drug discovery,” *Med. Res. Rev.*, 2026, doi: 10.1002/med.70074.
- [8] C. Jiménez-González, C. S. Ponder, Q. B. Broxterman, and J. B. Manley, “Using the right green yardstick: Why process mass intensity is used in the pharmaceutical industry to drive more sustainable processes,” *Org. Process Res. Dev.*, vol. 15, no. 4, pp. 912–917, 2011, doi: 10.1021/op200097d.
- [9] B. M. Trost, “The atom economy—A search for synthetic efficiency,” *Science*, vol. 254, no. 5037, pp. 1471–1477, 1991.
- [10] D. Prat, A. Wells, J. Hayler, H. Sneddon, C. R. McElroy, P. Abou-Shehade, *et al.*, “CHEM21 selection guide of classical- and less-classical solvents,” *Green Chem.*, vol. 18, pp. 288–296, 2016.
- [11] R. Gómez-Bombarelli, J. N. Wei, J. Duvenaud, J. M. Hernández-Lobato, B. Sánchez-Lengeling, D. Sheberla, *et al.*, “Automatic chemical design using a data-driven continuous representation of molecules,” *ACS Cent. Sci.*, vol. 4, no. 2, pp. 268–276, 2018.
- [12] W. Jin, R. Barzilay, and T. Jaakkola, “Junction tree variational autoencoder for molecular graph generation,” in *Proc. 35th Int. Conf. Mach. Learn.*, 2018, pp. 2323–2332.
- [13] C. W. Coley, L. Rogers, T. F. Jamison, and K. F. Jensen, “A graph-convolutional neural network model for the prediction of chemical reactivity,” *Chem. Sci.*, vol. 8, pp. 5638–5652, 2017.
- [14] D. Prat, J. Hayler, and A. Wells, “A survey of solvent selection guides,” *Green Chem.*, vol. 16, pp. 4546–4551, 2014.
- [15] B. J. Shields, J. Stevens, J. Li, M. Parasram, S. Damani, C. Alvarado, *et al.*, “Bayesian reaction optimization as a tool for chemical synthesis,” *Nature*, vol. 590, pp. 89–96, 2021.
- [16] J. Li, E. M. Simmons, and M. D. Eastgate, “A data-driven strategy for predicting greenness scores, rationally comparing synthetic routes and benchmarking PMI outcomes for the synthesis of molecules in the pharmaceutical industry,” *Green Chem.*, vol. 19, pp. 127–139, 2017, doi: 10.1039/C6GC02359B.
- [17] “Green chemistry and artificial intelligence: Emerging opportunities for sustainable chemical synthesis,” *Curr. Opin. Green Sustain. Chem.*, 2025.
- [18] A. Bender, M. C. Thomas, J. W. Scannell, D. A. Shaywitz, G. M. Ghiandoni, J. G. Greener, *et al.*, “Artificial intelligence in drug discovery—What it is, where we stand and the path forward,” *Nat. Rev. Drug Discov.*, 2026, doi: 10.1038/s41573-026-01496-2.
- [19] A. Gangwal and A. Lavecchia, “AI-driven synthesis in medicinal chemistry: Integrating large language models, robotic automation, and sustainability metrics to accelerate drug discovery,” *Med. Res. Rev.*, 2026, doi: 10.1002/med.70074.
- [20] “Green solvent selection and prediction using machine-learning approaches,” *ACS Omega*, 2021.
- [21] N. J. Turner and E. O'Reilly, “Biocatalytic retrosynthesis,” *Nat. Chem. Rev.*, 2023.
- [22] “Computational approaches for enzyme engineering and biocatalysis,” *Energy Environ. Sci.*, 2024.
- [23] “Automated flow chemistry and artificial intelligence for chemical synthesis,” *React. Chem. Eng.*, 2024.
- [24] “Machine-learning-assisted optimization of electrochemical synthesis,” *Chem. Catalysis*, 2024.
- [25] B. Burger, P. M. Maffettone, V. V. Gusev, C. M. Aitchison, Y. Bai, X. Wang, *et al.*, “A mobile robotic chemist,” *Nature*, vol. 583, pp. 237–241, 2020, doi: 10.1038/s41586-020-2442-2.
- [26] “Autonomous chemical synthesis and self-driving laboratories,” *Annu. Rev. Anal. Chem.*, 2025.
- [27] “Artificial intelligence and digital twins for pharmaceutical manufacturing,” *Int. J. Pharm.*, 2026.

- [28] “Quality by digital design and artificial intelligence in pharmaceutical manufacturing,” *Int. J. Pharm.*, 2026.
- [29] “Digitalization and sustainable pharmaceutical manufacturing,” *RSC Pharm.*, 2026.
- [30] “Artificial intelligence and green chemistry: Opportunities, limitations and future perspectives,” *Mater. Today, Chem.*, 2025.
- [31] B. A. Grzybowski, A. Żądło-Dobrowolska, N. Onishchenko, and E. S. Larsen, “Sustainable production of chemicals by algorithm-assisted (bio)synthesis,” *Nat. Rev. Bioeng.*, vol. 3, pp. 791–803, 2025.
- [32] B. Burger, P. M. Maffettone, V. V. Gusev, C. M. Aitchison, Y. Bai, X. Wang, *et al.*, “A mobile robotic chemist,” *Nature*, vol. 583, pp. 237–241, 2020.
- [33] C. Jiménez-González, C. S. Ponder, Q. B. Broxterman, and J. B. Manley, “Using the right green yardstick: Why process mass intensity is used in the pharmaceutical industry to drive more sustainable processes,” *Org. Process Res. Dev.*, vol. 15, no. 4, pp. 912–917, 2011.
- [34] L. Rogers and K. F. Jensen, “Continuous manufacturing—The Green Chemistry promise?” *Green Chem.*, vol. 21, pp. 3481–3498, 2019, doi: 10.1039/C9GC00773C.
- [35] A. Bender, M. C. Thomas, J. W. Scannell, D. A. Shaywitz, G. M. Ghiandoni, J. G. Greener, *et al.*, “Artificial intelligence in drug discovery—What it is, where we stand and the path forward,” *Nat. Rev. Drug Discov.*, 2026.
- [36] C. Castiello, P. Junghanns, A. Mergel, C. Jacob, C. Ducho, S. Valente, *et al.*, “GreenMedChem: The challenge in the next decade toward eco-friendly compounds and processes in drug design,” *Green Chem.*, vol. 25, pp. 2109–2169, 2023, doi: 10.1039/D2GC03772F.
- [37] A. Nuthi, B. U. Hirlekar, and V. A. Dixit, “Cumulative Green Chemistry Principle Score for objective assessment of drug synthesis,” *ACS Sustain. Chem. Eng.*, vol. 11, no. 45, pp. 16144–16155, 2023, doi: 10.1021/acssuschemeng.3c03961.
- [38] C. Jiménez-González, D. J. C. Constable, and C. S. Ponder, “Evaluating the ‘greenness’ of chemical processes and products in the pharmaceutical industry—A green metrics primer,” *Chem. Soc. Rev.*, vol. 41, pp. 1485–1498, 2012, doi: 10.1039/C1CS15215G.
- [39] E. R. Monteith, P. Mampuy, L. Summerton, J. H. Clark, B. U. W. Maes, and C. R. McElroy, “Why we might be misusing process mass intensity and a methodology to apply it effectively as a discovery level metric,” *Green Chem.*, vol. 22, pp. 123–135, 2020, doi: 10.1039/C9GC01537J.
- [40] C. Hu, C. J. Testa, S. C. Born, W. Wu, K. Shvedova, R. Sayin, *et al.*, “E-factor analysis of a pilot plant for end-to-end integrated continuous manufacturing of pharmaceuticals,” *Green Chem.*, vol. 22, pp. 4350–4360, 2020, doi: 10.1039/D0GC01397H.
- [41] R. A. Sheldon, “The E factor: Twenty-five years on,” *Green Chem.*, vol. 19, pp. 18–43, 2017, doi: 10.1039/C6GC02157C.
- [42] C. Castiello, P. Junghanns, A. Mergel, C. Jacob, C. Ducho, S. Valente, *et al.*, “GreenMedChem: Sustainable approaches to medicinal chemistry and pharmaceutical synthesis,” *Green Chem.*, vol. 25, pp. 2109–2169, 2023.
- [43] J. Li, E. M. Simmons, and M. D. Eastgate, “Data-driven prediction of synthetic-route greenness and PMI in pharmaceutical chemistry,” *Green Chem.*, vol. 19, pp. 127–139, 2017.
- [44] L. Rogers and K. F. Jensen, “Continuous manufacturing and green chemistry in pharmaceutical synthesis,” *Green Chem.*, vol. 21, pp. 3481–3498, 2019.
- [45] A. Gangwal and A. Lavecchia, “AI-driven synthesis in medicinal chemistry: Integrating LLMs, robotic automation and sustainability metrics,” *Med. Res. Rev.*, 2026, doi: 10.1002/med.70074.